Phaseline

Companies › Candid Therapeutics

Candid Therapeutics: clinical trials, targets and expected readouts

3 active drug programs in 6 registered trials: 6 Phase 1; Immunology, Neurology, Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CND261–Phase 1Rheumatoid ArthritisJun 2027
Cizutamig (CND106)
IGF-1 receptor antagonist
IGF1RPhase 1Generalized Myasthenia Gravis; Systemic Lupus Erythematosus (SLE); Thyroid Eye Disease, TED; Rheumatoid Arthritis (RA)Dec 2027
CND319–Phase 1Healthy Participants StudyMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07052032CND261Phase 1Rheumatoid ArthritisImmunologyJun 2027
NCT06946199Cizutamig (CND106)Phase 1Rheumatoid Arthritis (RA)ImmunologyJun 2027
NCT07215650Cizutamig (CND106)Phase 1Generalized Myasthenia GravisNeurologyDec 2027
NCT07215663Cizutamig (CND106)Phase 1Systemic Lupus Erythematosus (SLE)ImmunologyDec 2027
NCT07712939CND319Phase 1Healthy Participants StudyImmunologyMar 2028
NCT07597200Cizutamig (CND106)Phase 1Thyroid Eye Disease, TEDOphthalmologyMay 2028

Targets

IGF1R (1)

Companies with the same targets

Innovent Biologics (Suzhou) OHB Neonatology Amgen Viridian Therapeutics Minghui Pharmaceutical (Hangzhou) Sling Therapeutics Zai Lab (Shanghai)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.